Q301--New - QuantiFERON Testing Base + 4

Statement of Work

1.0 Purpose
Request the procurement of supplies and reagent to perform QuantiFERON®- TB Gold Plus testing on the DiaSorin LIAISON XL instrument

2.0 Scope
Vendor will provide blood collection tubes, reagents, and controls to perform testing utilizing the DiaSorin LIAISON XL instrument.

3.0 Location
The instrument will be located, and testing will be performed in the Client Services and Immunopathology (CSI) section of the Pathology & Laboratory Medicine Service at the VANTHCS, 4500 S. Lancaster Rd, Dallas, TX 75216.

4.0 Performance

Test Performance:
All tests, procedures, and equipment must perform at manufacturer s specifications. Deviations from the performance specifications shall be corrected by the Contractor.
Test performance will be evaluated by and not limited for performance thru peer comparison, quality control and CAP peer evaluation.
The vendor shall reimburse VANTHCS for any costs and/or supplies related to tests sent to a referral laboratory when testing is not available through no fault of the facility due to reagent problems, other product issues, instrumentation failure, or other factors. The assessed damages shall be applied to the invoice in the form of a credit or deduction.
Safety:
The Contractor shall immediately notify VANTHCS of any changes in reagent kit composition, procedure modification, recall notification, or any changes that will affect the performance of the test or procedure according to FDA regulations.

5.0 Period of Performance
Cost per Test Purchase Agreement for supplies and reagents will be in effect from December 01, 2026 through November 30, 2027 with four additional option years.

Base Period: December 01, 2026 through November 30, 2027
Option 1: December 01, 2027 through November 30, 2028
Option 2: December 01, 2028 through November 30, 2029
Option 3: December 01, 2029 through November 30, 2030
Option 4: December 01, 2030 through November 30, 2031

6.0 Deliverables/Supplies
Reagents and supplies will...